[go: up one dir, main page]

MXPA02002895A - Tratamiento topico de infecciones por estreptococcus. - Google Patents

Tratamiento topico de infecciones por estreptococcus.

Info

Publication number
MXPA02002895A
MXPA02002895A MXPA02002895A MXPA02002895A MXPA02002895A MX PA02002895 A MXPA02002895 A MX PA02002895A MX PA02002895 A MXPA02002895 A MX PA02002895A MX PA02002895 A MXPA02002895 A MX PA02002895A MX PA02002895 A MXPA02002895 A MX PA02002895A
Authority
MX
Mexico
Prior art keywords
streptococcal infections
therapeutic agent
topical treatment
streptococcal
composition
Prior art date
Application number
MXPA02002895A
Other languages
English (en)
Inventor
Lawrence Loomis
Original Assignee
New Horizons Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New Horizons Diagnostics Inc filed Critical New Horizons Diagnostics Inc
Publication of MXPA02002895A publication Critical patent/MXPA02002895A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MXPA02002895A 1999-09-14 2000-01-20 Tratamiento topico de infecciones por estreptococcus. MXPA02002895A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/395,637 US6056955A (en) 1999-09-14 1999-09-14 Topical treatment of streptococcal infections
PCT/US2000/001237 WO2001019391A1 (en) 1999-09-14 2000-01-20 Topical treatment of streptococcal infections

Publications (1)

Publication Number Publication Date
MXPA02002895A true MXPA02002895A (es) 2003-10-14

Family

ID=23563869

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02002895A MXPA02002895A (es) 1999-09-14 2000-01-20 Tratamiento topico de infecciones por estreptococcus.

Country Status (12)

Country Link
US (1) US6056955A (es)
EP (1) EP1212079A1 (es)
JP (1) JP2003509379A (es)
CN (1) CN1390135A (es)
AU (1) AU2617500A (es)
BR (1) BR0014512A (es)
CA (1) CA2383038A1 (es)
IL (1) IL148641A0 (es)
MX (1) MXPA02002895A (es)
NZ (1) NZ518059A (es)
WO (1) WO2001019391A1 (es)
ZA (1) ZA200202306B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157036A1 (en) * 2002-02-20 2003-08-21 Osborne David W. Topical dapsone for the treatment of acne
US6277399B1 (en) 1997-10-31 2001-08-21 New Horizon Diagnostics Corporation Composition incorporating bacterial phage associated lysing enzymes for treating dermatological infections
US6399097B1 (en) 1997-10-31 2002-06-04 New Horizons Diagnostics Corporation Composition for treatment of a bacterial infection of the digestive tract
US6264945B1 (en) 1997-10-31 2001-07-24 Vincent A Fischetti Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
US6432444B1 (en) * 1997-10-31 2002-08-13 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymes for treating dermatological infections
US20030129147A1 (en) * 1997-10-31 2003-07-10 Vincent Fischetti Use of bacterial phage associated lysing proteins for treating bacterial dental caries
US6423299B1 (en) 1997-10-31 2002-07-23 Vincent Fischetti Composition for treatment of a bacterial infection of an upper respiratory tract
US6428784B1 (en) * 1997-10-31 2002-08-06 New Horizons Diagnostics Corp Vaginal suppository for treating group B Streptococcus infection
US7232576B2 (en) 1997-10-31 2007-06-19 New Horizons Diagnostics Corp Throat lozenge for the treatment of Streptococcus Group A
US6335012B1 (en) 1997-10-31 2002-01-01 Vincent Fischetti Use of bacterial phage associated lysing enzymes for treating bacterial infections of the mouth and teeth
US20020136712A1 (en) * 1997-10-31 2002-09-26 Fischetti Vincent Bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of colonization and infections caused by streptococcus pneumoniae
US6248324B1 (en) 1997-10-31 2001-06-19 Vincent Fischetti Bacterial phage associated lysing enzymes for treating dermatological infections
US6056954A (en) 1997-10-31 2000-05-02 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses
US20030082110A1 (en) * 1997-10-31 2003-05-01 Vincent Fischetti Use of bacterial phage associated lysing proteins for treating bacterial dental caries
US6326002B1 (en) 1997-10-31 2001-12-04 New Horizons Diagnostics Corporation Use of bacterial phage associated lysing enzymes for treating streptococcal infections of the upper respiratory tract
WO2004064732A2 (en) * 2003-01-16 2004-08-05 New Horizons Diagnostics Corporation The use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl
US20030129146A1 (en) * 1997-10-31 2003-07-10 Vincent Fischetti The use of bacterial phage associated lysing proteins for treating bacterial dental caries
US6752988B1 (en) 2000-04-28 2004-06-22 New Horizons Diagnostic Corp Method of treating upper resiratory illnesses
US6406692B1 (en) * 1997-10-31 2002-06-18 New Horizons Diagnostics Corp Composition for treatment of an ocular bacterial infection
US6399098B1 (en) 1997-10-31 2002-06-04 New Horizons Diagnostics Corp Composition for treating dental caries caused by streptococcus mutans
US20020127215A1 (en) * 1999-09-14 2002-09-12 Lawrence Loomis Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
US7063837B2 (en) * 1999-09-14 2006-06-20 New Horizons Diagnostics Corp Syrup composition containing phage associated lytic enzymes
AU2001259205A1 (en) * 2000-04-28 2001-11-12 New Horizons Diagnostic Corporation The use of bacterial phage associated lysing enzymes for treating various illnesses
US6395504B1 (en) 2000-09-01 2002-05-28 New Horizons Diagnostics Corp. Use of phage associated lytic enzymes for the rapid detection of bacterial contaminants
EP1333854A4 (en) * 2000-11-02 2005-10-05 New Horizons Diagnostics Corp USE OF BACTERIAL PHAGS IN CONNECTION WITH LYSEENZYMS FOR PREVENTING FOOD DRUGS
WO2003000010A2 (en) * 2001-06-20 2003-01-03 Mayo Foundation For Medical Education And Research Adenosyl-cobalamin fortified compositions
US20040213765A1 (en) * 2001-07-13 2004-10-28 Vincent Fischetti Use of bacterial phage associated lytic enzymes to prevent food poisoning
MXPA04002899A (es) * 2001-09-27 2005-07-01 Gangen Inc Bacteriofagos deficientes en lisina, que tienen inmunogenicidad reducida.
US6759229B2 (en) * 2001-12-18 2004-07-06 President & Fellows Of Harvard College Toxin-phage bacteriocide antibiotic and uses thereof
US7452533B2 (en) * 2002-03-26 2008-11-18 Biosynexus Incorporated Antimicrobial polymer conjugate containing lysostaphin and polyethylene glycol
US20040081646A1 (en) * 2002-08-29 2004-04-29 Engler Jeffrey A. Group B Streptococcal phage lysin
US20050129711A1 (en) * 2002-11-14 2005-06-16 Janakiraman Ramachandran Incapacitated whole-cell immunogenic bacterial compositions produced by recombinant expression
WO2004052308A2 (en) * 2002-12-10 2004-06-24 Biosynexus Incorporated Topical anti-infective formulations
WO2004104213A2 (en) * 2003-05-15 2004-12-02 The Rockefeller University Nucleic acids and polypeptides of c1 bacteriophage and uses thereof
US20060204526A1 (en) * 2003-08-13 2006-09-14 Lathrop Robert W Emulsive composition containing Dapsone
MXPA06001713A (es) * 2003-08-13 2007-01-26 Qlt Usa Inc Composicion de emulsion que contiene dapsone.
US7569223B2 (en) * 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
CN1315532C (zh) * 2004-10-19 2007-05-16 上海新药研究开发中心 复合溶菌酶Lysoamidase喷雾剂及制备方法
EP1814574A4 (en) 2004-10-27 2009-08-05 Univ Denver ANALOGUE OF ADRENOCORTICOTROPEN HORMON AND CORRESPONDING METHODS
US20060271262A1 (en) * 2005-05-24 2006-11-30 Mclain Harry P Iii Wireless agricultural network
US8389469B2 (en) * 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
US7582291B2 (en) * 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
WO2007024628A2 (en) 2005-08-24 2007-03-01 The Rockefeller University Ply-gbs mutant lysins
US20070116749A1 (en) * 2005-11-21 2007-05-24 Grossman Leonard D Method for treatment of cellulitis
KR100781669B1 (ko) * 2006-06-20 2007-12-03 주식회사 인트론바이오테크놀로지 황색포도상구균 특이적 사멸능을 갖는 박테리오파지
KR100759988B1 (ko) * 2006-08-04 2007-09-19 주식회사 인트론바이오테크놀로지 황색포도상구균에 특이적인 항균 단백질
KR100910961B1 (ko) * 2007-09-13 2009-08-05 주식회사 인트론바이오테크놀로지 황색포도상구균의 균막 처치에 효과적인 박테리오파지 또는그것 유래의 용균단백질
JP2011513304A (ja) 2008-02-27 2011-04-28 アラーガン、インコーポレイテッド 酒さを処置するためのダプソン
WO2009114520A2 (en) * 2008-03-10 2009-09-17 Pharmain Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
US20100029781A1 (en) * 2008-06-04 2010-02-04 Morris Jerome A Methods for preparation of anti-acne formulation and compositions prepared thereby
WO2009150171A1 (en) * 2008-06-10 2009-12-17 Profos Ag Method of treatment of inflammatory diseases
US8043613B2 (en) * 2009-02-12 2011-10-25 Intron Biotechnology, Inc. Podoviriedae bacteriophage having killing activity specific to Staphylococcus aureus
US8377866B2 (en) * 2009-02-12 2013-02-19 Intron Biotechnology, Inc. Antimicrobial protein derived from Podoviridae bacteriophage specific to Staphylococcus aureus
CN102198265B (zh) * 2011-03-22 2013-08-28 上海交通大学 应用噬菌体裂解酶降解猪链球菌生物被膜的方法
MX336427B (es) 2011-04-21 2016-01-18 Univ Rockefeller Lisinas de bacteriofago de estreptococcus para la deteccion y tratamiento de bacterias gram positivas.
EP2764093B1 (en) 2011-10-05 2018-04-18 The Rockefeller University Dimeric bacteriophage lysins
US9757328B2 (en) * 2012-03-29 2017-09-12 Murami Pharma, Inc. Lysozyme gel formulations
ES2729123T3 (es) 2012-05-09 2019-10-30 Contrafect Corp Rotura de biopelícula con lisina plyss2
US10813983B2 (en) 2012-05-09 2020-10-27 Contrafect Corporation Bacteriophage lysin and antibiotic combinations against gram positive bacteria
CN102961324B (zh) * 2012-11-16 2014-06-25 沈阳药科大学 一种溶菌酶眼用凝胶剂及其制备方法
US11173163B2 (en) * 2015-08-05 2021-11-16 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
BR112018073205A2 (pt) 2016-05-12 2019-02-19 Contrafect Corporation método de microdiluição em caldo para avaliação e determinação da concentração inibitória mínima de polipeptídeos antibacterianos
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
CN112384199A (zh) 2018-06-04 2021-02-19 阿尔库缇斯股份有限公司 改善罗氟司特皮肤渗透滞后时间的方法和制剂
KR20230146513A (ko) 2020-12-04 2023-10-19 아큐티스 바이오테라퓨틱스, 인크. 항진균 특성을 갖는 국소 로플루밀라스트 제형
WO2023129215A1 (en) 2021-12-28 2023-07-06 Arcutis Biotherapeutics, Inc. Topical roflumilast aerosol foams
IL319352A (en) 2022-09-15 2025-05-01 Arcutis Biotherapeutics Inc Pharmaceutical preparations of roflumilast and solvents capable of dissolving high amounts of the drug

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1542848A (en) * 1975-06-11 1979-03-28 Searle & Co Anti-mycotic pharmaceutical compositions containing enzymes
FR2357246A1 (fr) * 1976-07-09 1978-02-03 Martinez Gerard Nouvelles compositions therapeutiques douees d'activite anti-inflammatoire, antalgique et anti-cellulitique
AU8108587A (en) * 1986-10-08 1988-05-06 David Bernstein Method for exposing group a streptococcal antigens and an improved diagnostic test for the identification of group a streptococci
RU2064299C1 (ru) * 1993-12-13 1996-07-27 Всероссийский научно-исследовательский институт ветеринарной санитарии, гигиены и экологии Препарат для лечения мастита крупного рогатого скота "лизомаст"
RU2103991C1 (ru) * 1995-08-14 1998-02-10 Научно-производственное объединение "Иммунопрепарат" Средство для лечения стрептококковых заболеваний
US5997862A (en) * 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections

Also Published As

Publication number Publication date
US6056955A (en) 2000-05-02
WO2001019391A1 (en) 2001-03-22
CA2383038A1 (en) 2001-03-22
IL148641A0 (en) 2002-09-12
NZ518059A (en) 2003-09-26
ZA200202306B (en) 2002-12-24
BR0014512A (pt) 2002-06-18
AU2617500A (en) 2001-04-17
JP2003509379A (ja) 2003-03-11
EP1212079A1 (en) 2002-06-12
CN1390135A (zh) 2003-01-08

Similar Documents

Publication Publication Date Title
MXPA02002895A (es) Tratamiento topico de infecciones por estreptococcus.
DK0806941T3 (da) Liposomalt antibakterielt præparat med lav fasthed
IL136839A0 (en) Pharmaceutical compositions comprising cannabidiol derivatives
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
GB2357969A (en) Improvements in or relating to the treatment of lesions
GB9905425D0 (en) Pharmaceutical composition
YU18899A (sh) L-nukleozidi purina, njihovi analogoni i primena
GB0021317D0 (en) Transdermal pharmaceutical delivery composition
BR9917152A (pt) Composição para tratamento terapêutico ou profilático de infecção estreptocócica e método e uso respectivos
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
MXPA04000654A (es) Terapia dermica usando derivados de fosfato de agente de transferencia de electrones.
WO2005007072A3 (en) Methods and pharmaceutical compositions for healing wounds
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
AU1865100A (en) Hyaluronate lyase used for promoting penetration in topical agents
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
AU5643299A (en) Humic acid and its use in the treatment of various conditions
AU2420001A (en) Methods and compositions for the treatment of pain
EP1023901A4 (en) MEDICINES FOR HEPATITIS C AND THE USE THEREOF
WO2001085188A3 (en) Use of echinacea as a hematinic agent
AU2001267561A1 (en) Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined withspecific pharmaceutical active agents
GEP20043231B (en) Resorcinol Composition
CO5031290A1 (es) Formulacion lo
AU2002236587A1 (en) Compositions for adhesion prevention
CA2336773A1 (en) Component b as angiogenic agent in combination with human growth factors
JP2002520292A5 (ja) ヒト成長因子と組み合わせた脈管形成剤としてのコンポーネントｂの使用

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees